Vial

Vial has dosed first participants in the Phase I trial of Vial's IL13 x TSLP bi-specific antibody for Asthma, COPD and other immunologic indications. The milestone marks a major step forward for the program. Read more on today's announcement here: https://lnkd.in/gdsdWgrf

Despite their effects, GLP‑1-based therapies fall short for many patients. Dr. Samuel Klein MD, the Director for the Center of Human Nutrition at WashU noted that patients on GLP-1s experience very heterogenous response, including uneven weight-loss, intolerable side effects, and high dropout rates. This suggests an urgent need for a more targeted and more sustainable treatment for obesity, like Vial’s INHBE siRNA program, which was designed to have a more targeted MoA and higher tolerability to mitigate discontinuation. Discover Vial’s INHBE program: https://lnkd.in/ghEUN_kE

The benefits of GLP‑1s are often overshadowed by their side effects, with many patients discontinuing treatment within the first year. According to Dr. Tim Garvey MD, of UAB, obesity is a lifelong disease, and patients need more tolerable and sustainable options. Vial’s INHBE siRNA is the perfect solution, as the therapeutic is designed to be more targeted, more tolerable, and focused on reducing adiposity to enable quality weight loss rather than simply restricting calories. Discover Vial’s INHBE program: https://lnkd.in/ghEUN_kE

GLP‑1s have transformed obesity care, but they are not right for everyone. Obesity expert and researcher Dr. Lawrence Cheskin MD outlines which patients could benefit from Vial’s INHBE siRNA program, a novel target designed to drive meaningful weight loss and support long‑term health. Discover Vial’s INHBE program: https://lnkd.in/ghEUN_kE

As obesity treatments advance, it’s crucial to address unmet needs of specific patient populations. Dr. Jens Juul Holst from the University of Copenhagen highlights why preserving muscle in older adults is key, especially as age-related injuries and falls remain major risks. Unlike GLP-1s, Vial’s INHBE siRNA program targets fat specifically, sparing lean muscle and enabling both generalized and population-tailored weight loss. Discover Vial’s INHBE program: https://lnkd.in/ghEUN_kE

Vial is geared up to attend the 44th Annual J.P. Morgan Healthcare Conference in San Francisco next week! Reach out to us — we’d love to meet. See you all there!

Vial is geared up to attend the 44th Annual J.P. Morgan Healthcare Conference in San Francisco next week! Reach out to us — we’d love to meet. See you all there!

The prevalence of comorbidity in patients with obesity is high, which can have severe health implications. Nephrologist and best-selling author of The Obesity Code, Dr. Jason Fung, MD, believes that targeting fat distribution via INHBE is beneficial for overall metabolic health. This highlights Vial’s INHBE siRNA program as a promising therapeutic approach to not only improve the quality of fat loss but also address the overall distribution of fat. Discover Vial’s INHBE program: https://lnkd.in/ghEUN_kE

GI intolerance of GLP-1s is a major problem for those currently on the obesity treatment. Dr. Lee Kaplan MD, Director of Dartmouth Health’s Weight and Wellness Center, suggests new MoAs to tackle this issue and highlights Vial’s INHBE siRNA program as a promising target to compliment and potentially enhance current treatments. Discover Vial’s INHBE program: https://lnkd.in/ghEUN_kE

While patients on GLP-1s lose weight, the drug does not target the underlying cause for obesity - adipose tissue. Here, Dr. Arya M. Sharma, MD, DSc (hon), FRCPC, FCAHS, Professor Emeritus at the University of Alberta, emphasizes how Vial’s INHBE siRNA directly impacts the function of adipose tissue to better address cellular hypertrophy and inflammation. Discover Vial’s INHBE program: https://lnkd.in/ghEUN_kE